What is the 13F Pro Quality Score for ACAD?

13F Pro ranks ACADIA PHARMACEUTICALS INC (ACAD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACAD's current score at https://13fpro.ai/research/ACAD (free sign-up required for the full ranking).

Which hedge funds own the most ACAD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ACAD include BAKER BROS. ADVISORS, BlackRock,, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ACAD as soon as new 13F filings post.

Where does 13F Pro source ACAD data?

All ACADIA PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ACADIA PHARMACEUTICALS INC files with the SEC under CIK 1070494. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACAD in?

ACADIA PHARMACEUTICALS INC (ACAD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ACAD's revenue?

Per ACADIA PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: NUPLAZID ($166.9M, +4.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/ACAD.

What are ACAD's largest expenses?

ACADIA PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Research and development ($76.9M, -1.8% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is ACAD research updated on 13F Pro?

ACAD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ACADIA PHARMACEUTICALS INC(ACAD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1070494 ACAD stock profile & AI dashboard →

13F Pro Quality Score

69.8/100

Rank #345 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

82.9/100

Profitability

79.2/100

Balance Sheet

80.9/100

Earnings Quality

30.0/100

Free Cash Flow

76.4/100

Institutional Flow

68.5/100

Revenue Scale

50.5/100

Dilution Risk

26.2/100

ACAD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ACADIA PHARMACEUTICALS INC (ACAD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACAD at 69.8/100 on a 32-signal composite quality model, placing it at rank #345 of 2,879 stocks — the top 25% of the AI-ranked universe. ACAD scores in the top quartile across revenue growth (82.9), balance sheet strength (80.9), profitability (79.2). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ACADIA PHARMACEUTICALS INC reports quarterly revenue of $268.1M, net income of $3.6M, free cash flow of $28.8M. Top institutional holders of ACAD by reported 13-F value include BAKER BROS. ADVISORS, BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ACAD trades on the Nasdaq exchange and files with the SEC under CIK 1070494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACAD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACADIA PHARMACEUTICALS INC directly from SEC EDGAR. ACADIA PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 73 since 2021, currently 69.8 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ACADIA PHARMACEUTICALS INC

Quirks, history, and lore behind ACAD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-to-mid cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of a few hundred million dollars, driven almost entirely by a single approved drug — a high-risk, high-reward model familiar to specialty pharma investors.
3
The History
Founded in the early 2000s, the company spent years in clinical-stage limbo before winning a landmark FDA approval in 2016 for a drug targeting a notoriously hard-to-treat neurological condition.
4
The Secret
Its flagship drug works on the serotonin 5-HT2A receptor — a mechanism shared with certain psychedelics — making it a pioneer in central nervous system pharmacology.
5
The Lore
Its approved drug, pimavanserin, was the first new treatment for Parkinson's disease psychosis in decades — a condition most big pharma had quietly given up on.
6
The Giveaway
Ticker rhymes with a scenic national park in Maine, and its drug Nuplazid remains the only FDA-approved therapy specifically for Parkinson's disease psychosis.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ACAD's Business? Latest 10-Q Breakdown

AI-extracted from ACADIA PHARMACEUTICALS INC's 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q1 2026 net product sales of $268.1M (+9.8% YoY) driven by NUPLAZID and DAYBUE growth, but operating loss of $4.6M due to 35% surge in SG&A spending.

Biggest Revenue Drivers

Total revenue: $268.1M+9.8% YoY

NUPLAZID$166.9M+4.5% YoY

Growth in NUPLAZID unit sales in 2026 compared to 2025

Largest Expense Items

Research and development$76.9M-1.8% YoY

Remained relatively flat; includes costs for remlifanserin, early-stage programs, and post-marketing requirements for DAYBUE

Watch Items from the Filing

EMA issued negative CHMP opinion on trofinetide MAA in February 2026; company requested re-examination, which may not be favorable. Failure to obtain EU approval would limit trofinetide commercial revenues outside North America.
Accumulated deficit of $1.81B as of March 31, 2026; though company achieved three-year cumulative profitability and reduced valuation allowance in FY2025, near-term Q1 2026 operating loss suggests continued cash burn risk.
Company may be required to pay up to $3.6B in aggregate milestone payments across pipeline programs. Neuren licensing agreements alone obligate up to $1.26B in potential milestone payments on trofinetide and NNZ-2591.
Securities class action, opt-out litigation, and derivative suit pending; derivative settlement in principle approved with $1.5M attorneys' fees, subject to court approval. Unpredictable litigation costs could materially impact results.
NUPLAZID has Orange Book patent protection; generic competition from Aurobindo, MSN, and Zydus blocked until 2036–2038 under settlement agreements. Multiple ANDA infringement cases remain on appeal.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$268.1M

Net Income

Q1 2026

$3.6M

Free Cash Flow

Q1 2026

$28.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+31.8% YoY

$957.8MFY 2024

FY20 $441.8MFY22 $517.2MFY23 $726.4MFY24 $957.8M

Net Income

+470.5% YoY

$226.0MFY 2024

FY20 $-281.6MFY22 $-216.0MFY23 $-61.0MFY24 $226.0M

Operating Income

+414.5% YoY

$230.8MFY 2024

FY20 $-286.6MFY22 $-223.6MFY23 $-73.4MFY24 $230.8M

EPS (Diluted)

+467.6% YoY

$1.36FY 2024

FY20 $-1.79FY22 $-1.34FY23 $-0.37FY24 $1.36

Total Assets

+58.6% YoY

$1.19BFY 2024

FY20 $782.6MFY22 $587.8MFY23 $749.0MFY24 $1.19B

Op. Cash Flow

+844.3% YoY

$157.7MFY 2024

FY20 $-136.2MFY22 $-114.0MFY23 $16.7MFY24 $157.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$957.8M +31.8%	$726.4M +40.4%	$517.2M +17.1%	$441.8M +30.3%	$339.1M +51.5%	$223.8M
Net Income	$226.0M +470.5%	$-61.0M +71.8%	$-216.0M +23.3%	$-281.6M -19.7%	$-235.3M +4.1%	$-245.2M
Operating Income	$230.8M +414.5%	$-73.4M +67.2%	$-223.6M +22.0%	$-286.6M -16.2%	$-246.5M +0.4%	$-247.4M
EPS (Diluted)	$1.36 +467.6%	$-0.37 +72.4%	$-1.34 +25.1%	$-1.79	—	—
Total Assets	$1.19B +58.6%	$749.0M +27.4%	$587.8M -24.9%	$782.6M -0.1%	$783.2M +45.0%	$540.2M
Operating Cash Flow	$157.7M +844.3%	$16.7M +114.6%	$-114.0M +16.3%	$-136.2M +9.9%	$-151.1M +9.8%	$-167.5M

Get alerted when ACAD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ACADIA PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACAD

BAKER BROS. ADVISORS LP
$954.9M42,896,690 sh
BlackRock, Inc.
$479.7M21,550,921 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$193.0M8,671,645 sh
STATE STREET CORP
$185.5M8,332,771 sh
RTW INVESTMENTS, LP
$159.0M7,144,524 sh
VANGUARD CAPITAL MANAGEMENT LLC
$126.0M5,661,400 sh
GEODE CAPITAL MANAGEMENT, LLC
$77.1M3,464,689 sh
FIRST TRUST ADVISORS LP
$74.4M3,343,868 sh
DIMENSIONAL FUND ADVISORS LP
$70.2M3,155,160 sh
Palo Alto Investors LP
$63.9M2,872,695 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$954.9M	42,896,690
BlackRock, Inc.	$479.7M	21,550,921
VANGUARD PORTFOLIO MANAGEMENT LLC	$193.0M	8,671,645
STATE STREET CORP	$185.5M	8,332,771
RTW INVESTMENTS, LP	$159.0M	7,144,524
VANGUARD CAPITAL MANAGEMENT LLC	$126.0M	5,661,400
GEODE CAPITAL MANAGEMENT, LLC	$77.1M	3,464,689
FIRST TRUST ADVISORS LP	$74.4M	3,343,868
DIMENSIONAL FUND ADVISORS LP	$70.2M	3,155,160
Palo Alto Investors LP	$63.9M	2,872,695

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACAD on your watchlist

Track score changes the day ACADIA PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACAD a good stock to buy?

13F Pro's AI-powered analysis of ACADIA PHARMACEUTICALS INC (ACAD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACAD are available on the ACAD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ACAD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACAD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACADIA PHARMACEUTICALS INC's investment landscape.